Human Papillomavirus (HPV)
EACS 2017: European AIDS Clinical Society Strengthens HPV Vaccination Advice
- Details
- Category: Human Papillomavirus (HPV)
- Published on Tuesday, 07 November 2017 00:00
- Written by Keith Alcorn
The European AIDS Clinical Society (EACS) has recommended human papillomavirus (HPV) vaccination for everyone living with HIV aged under 26 and all men who have sex with men up to the age of 40.
PAS 2017: Vaccine Reduces Human Papillomavirus Prevalence Among Young Women
- Details
- Category: HPV Vaccines
- Published on Tuesday, 16 May 2017 00:00
- Written by Liz Highleyman
The prevalence of human papillomavirus (HPV) types included in the most widely used vaccine has decreased among adolescent and young women in the U.S., with "herd immunity" extending to those who were not vaccinated themselves, according to study results presented at the Pediatric Academic Societies Meeting last week in San Francisco.
Gardasil HPV Vaccine Reduces Occurrence of Genital Warts and Cervical Dysplasia
- Details
- Category: Human Papillomavirus (HPV)
- Published on Thursday, 30 June 2016 00:00
- Written by Liz Highleyman
Countries that widely use a quadrivalent human papillomavirus (HPV) vaccine have seen up to a 90% reduction in HPV infections and decreases in the incidence of genital warts and cervical cell abnormalities that can lead to cancer, according to an analysis of nearly 60 studies from 9 countries presented at the European Research Organization on Genital Infection and Neoplasia and published in the May 26 edition of Clinical Infectious Diseases.
Young Adolescents Need Only 2 Doses of Human Papillomavirus Vaccine, CDC Says
- Details
- Category: HPV Vaccines
- Published on Tuesday, 08 November 2016 00:00
- Written by Liz Highleyman
Adolescents age 11-14 years can receive 2 doses of the human papillomavirus (HPV) vaccine to prevent cancers caused by HPV, rather than the 3 doses previously recommended, according to the U.S. Centers for Disease Control and Prevention (CDC). This change is supported by a systematic review presented at the recent IDWeek meeting in New Orleans, which found that 2 vaccine doses were non-inferior to 3 doses for this age group.
ASCO 2016: PD-1 Blocker Nivolumab Shows Promise for Advanced Anal Cancer
- Details
- Category: Anal & Cervical Cancer
- Published on Monday, 06 June 2016 00:00
- Written by MD Anderson Cancer Center
The checkpoint inhibitor nivolumab(Opdivo), a monoclonal antibody targeting the PD-1 receptor, demonstrated activity against metastatic anal cancer that in patients who did not respond to prior treatment, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. 70% of participants in this small study experienced complete or partial response or stabilized disease.
Web Design and Development by